Zalifrelimab
- Generic Name
- Zalifrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2148321-69-9
- Unique Ingredient Identifier
- FE7L22H028
- Background
Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
SUO 2024: A Phase I Dose-Escalation Study of UGN-301 (Zalifrelimab) as ...
A phase I dose-escalation study of UGN-301 (Zalifrelimab) in recurrent non-muscle invasive bladder cancer (NMIBC) was presented at the 2024 SUO annual meeting. The study evaluates UGN-301 as monotherapy and in combination with other agents to determine safety and recommended phase II dose, aiming to address the high recurrence and progression rates in NMIBC.
New Targeted Therapies and Combinations of Treatments in Gynecological Cancer Research
2021 saw significant advances in gynecological cancer research, focusing on cervical, endometrial, and ovarian cancers. Key developments included innovative therapies, improved screening and prevention strategies, and promising results from immunotherapy and antibody-drug conjugates. Despite COVID-19, research remained active, offering hope for future medical practice changes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath